IN2012DN00640A - - Google Patents

Download PDF

Info

Publication number
IN2012DN00640A
IN2012DN00640A IN640DEN2012A IN2012DN00640A IN 2012DN00640 A IN2012DN00640 A IN 2012DN00640A IN 640DEN2012 A IN640DEN2012 A IN 640DEN2012A IN 2012DN00640 A IN2012DN00640 A IN 2012DN00640A
Authority
IN
India
Prior art keywords
variable domains
hosts
ligands
vectors
compositions
Prior art date
Application number
Other languages
English (en)
Inventor
Coulstock Edward
De Angelis Elena
Liu Haiqun
Schon Oliver
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of IN2012DN00640A publication Critical patent/IN2012DN00640A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/31Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
IN640DEN2012 2009-07-16 2010-07-14 IN2012DN00640A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22602809P 2009-07-16 2009-07-16
US30755410P 2010-02-24 2010-02-24
PCT/EP2010/060112 WO2011006915A2 (en) 2009-07-16 2010-07-14 Improved anti-serum albumin binding single variable domains

Publications (1)

Publication Number Publication Date
IN2012DN00640A true IN2012DN00640A (ko) 2015-08-21

Family

ID=42829253

Family Applications (1)

Application Number Title Priority Date Filing Date
IN640DEN2012 IN2012DN00640A (ko) 2009-07-16 2010-07-14

Country Status (15)

Country Link
US (2) US8679496B2 (ko)
EP (1) EP2454285A2 (ko)
JP (1) JP2012532620A (ko)
KR (1) KR20120038494A (ko)
CN (1) CN102574914A (ko)
AU (1) AU2010272590B2 (ko)
BR (1) BR112012001681A2 (ko)
CA (1) CA2768462A1 (ko)
EA (1) EA201270174A1 (ko)
IL (1) IL217520A0 (ko)
IN (1) IN2012DN00640A (ko)
MX (1) MX2012000765A (ko)
SG (1) SG177601A1 (ko)
WO (1) WO2011006915A2 (ko)
ZA (1) ZA201200276B (ko)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010094720A2 (en) * 2009-02-19 2010-08-26 Glaxo Group Limited Improved anti-tnfr1 polypeptides, antibody variable domains & antagonists
MX2012000765A (es) * 2009-07-16 2012-02-13 Glaxo Group Ltd Dominios variables sencillos de union de albumina anti-suero mejorados.
EP2603522A1 (en) 2010-08-13 2013-06-19 GlaxoSmithKline Intellectual Property Development Limited Improved anti-serum albumin binding variants
WO2012072731A2 (en) * 2010-12-01 2012-06-07 Glaxo Group Limited Improved anti-serum albumin binding single variable domains
PT2776466T (pt) 2011-11-11 2017-11-30 Ucb Biopharma Sprl Anticorpos de ligação a albumina e seus fragmentos de ligação
GB201200563D0 (en) * 2012-01-13 2012-02-29 Imp Innovations Ltd Binding molecule
WO2017041114A2 (en) * 2015-09-03 2017-03-09 The Children's Mercy Hospital Anti-nicotinamide phosphoribosyltransferase antibody genes and methods of use thereof
NO2768984T3 (ko) 2015-11-12 2018-06-09
CA3005061A1 (en) * 2015-11-13 2017-05-18 Ablynx Nv Improved serum albumin-binding immunoglobulin variable domains
EP3377526A1 (en) 2015-11-18 2018-09-26 Merck Sharp & Dohme Corp. PD1/CTLA4 Binders
CR20180279A (es) 2015-11-18 2018-08-24 Merck Sharp & Dohme Enlazadores de ctla4
IL300122A (en) 2015-11-18 2023-03-01 Merck Sharp ַ& Dohme Llc Substances that bind to PD1 and/or LAG3
EP3377525A2 (en) 2015-11-18 2018-09-26 Ablynx NV Improved serum albumin binders
WO2018104444A1 (en) * 2016-12-07 2018-06-14 Ablynx Nv Improved serum albumin binding immunoglobulin single variable domains
KR102653724B1 (ko) 2017-01-17 2024-04-02 아블린쓰 엔.브이. 개선된 혈청 알부민 결합제
US11414481B2 (en) 2017-01-17 2022-08-16 Ablynx N.V. Serum albumin binders
WO2018151868A2 (en) 2017-02-16 2018-08-23 Sonnet Bio Therapeutics Albumin binding domain fusion proteins
US20230192897A1 (en) 2017-10-10 2023-06-22 Numab Therapeutics AG Multispecific antibody
EP3470426A1 (en) 2017-10-10 2019-04-17 Numab Therapeutics AG Multispecific antibody
CN113508134A (zh) * 2019-02-22 2021-10-15 安维达生物科技公司 白蛋白结合抗体及其用途
EP3816185A1 (en) 2019-11-04 2021-05-05 Numab Therapeutics AG Multispecific antibody directed against pd-l1 and a tumor-associated antigen
GB201919061D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibody
WO2021205183A1 (en) 2020-04-09 2021-10-14 Autolus Limited Polypeptide
GB202007441D0 (en) 2020-05-19 2020-07-01 Autolus Ltd Polypeptide
EP3915580A1 (en) 2020-05-29 2021-12-01 Numab Therapeutics AG Multispecific antibody
EP3988568A1 (en) 2020-10-21 2022-04-27 Numab Therapeutics AG Combination treatment
MX2023006650A (es) 2020-12-07 2023-06-21 UCB Biopharma SRL Anticuerpos multiespecificos y combinaciones de anticuerpos.
AU2022215847A1 (en) 2021-02-02 2023-08-10 Numab Therapeutics AG Multispecific antibodies having specificity for ror1 and cd3
EP4183800A1 (en) 2021-11-19 2023-05-24 Medizinische Hochschule Hannover Novel sars-cov-2 neutralizing antibodies
WO2024038095A1 (en) 2022-08-16 2024-02-22 Iome Bio NOVEL ANTI-RGMb ANTIBODIES

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
IL159177A0 (en) * 2001-06-20 2004-06-01 Prochon Biotech Ltd Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
US20100081792A1 (en) * 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
PT1517921E (pt) 2002-06-28 2006-09-29 Domantis Ltd Ligandos duplamente especificos com semi-vida no soro aumentada
DK1737962T3 (da) 2004-03-24 2010-12-13 Domantis Ltd GAS1-universel leder
CA2569240A1 (en) 2004-06-01 2005-12-15 Domantis Limited Drug fusion comprising a polypeptide drug and an immunoglobulin heavy chain variable domain specific for serum albumin
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
GB0521621D0 (en) * 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
CN101128487B (zh) 2004-12-02 2012-10-10 杜门蒂斯有限公司 靶向血清白蛋白和glp-1或pyy的双特异性结构域抗体
WO2007063311A2 (en) * 2005-12-01 2007-06-07 Domantis Limited Competitive domain antibody formats that bind interleukin 1 receptor type 1
TW200730539A (en) * 2005-12-01 2007-08-16 Domantis Ltd Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
EP1966242A1 (en) * 2005-12-06 2008-09-10 Domantis Limited Ligands that have binding specificity for egfr and/or vegf and methods of use therefor
AU2007209201A1 (en) 2006-01-24 2007-08-02 Domantis Limited Fusion proteins that contain natural junctions
CN101578298A (zh) * 2006-01-24 2009-11-11 杜门蒂斯有限公司 结合il-4和/或il-13的配体
KR20100018040A (ko) 2007-06-06 2010-02-16 도만티스 리미티드 프로테아제 내성 폴리펩티드를 선택하는 방법
WO2009149143A1 (en) * 2008-06-03 2009-12-10 E. I. Du Pont De Nemours And Company Adhesion of polyamides to epoxy resins
US8906035B2 (en) * 2008-06-04 2014-12-09 Ethicon Endo-Surgery, Inc. Endoscopic drop off bag
BRPI0913623A8 (pt) * 2008-06-06 2017-10-03 Danisco Us Inc Composições e métodos compreendendo variantes de proteases microbianas
US10198891B2 (en) * 2008-06-06 2019-02-05 Epona Llc System and method for regulating fuel transactions
MX2012000765A (es) * 2009-07-16 2012-02-13 Glaxo Group Ltd Dominios variables sencillos de union de albumina anti-suero mejorados.

Also Published As

Publication number Publication date
SG177601A1 (en) 2012-02-28
KR20120038494A (ko) 2012-04-23
EP2454285A2 (en) 2012-05-23
CN102574914A (zh) 2012-07-11
AU2010272590A1 (en) 2012-02-02
IL217520A0 (en) 2012-02-29
ZA201200276B (en) 2012-09-26
JP2012532620A (ja) 2012-12-20
MX2012000765A (es) 2012-02-13
BR112012001681A2 (pt) 2019-09-24
EA201270174A1 (ru) 2012-07-30
CA2768462A1 (en) 2011-01-20
US8679496B2 (en) 2014-03-25
US20140140996A1 (en) 2014-05-22
US20120114647A1 (en) 2012-05-10
WO2011006915A3 (en) 2011-03-03
WO2011006915A2 (en) 2011-01-20
AU2010272590B2 (en) 2013-10-10

Similar Documents

Publication Publication Date Title
IN2012DN00640A (ko)
MX2011008752A (es) Variantes de union a anti-albumina de suero mejoradas.
MX2012013406A (es) Variantes de union mejoradas anti-albumina serica.
MX2011008749A (es) Variantes de union a anti-albumina de suero mejoradas.
CY1119567T1 (el) Θεραπευτικα πεπτιδια
WO2014083208A9 (en) Binding proteins comprising at least two repeat domains against her2
MX2012003939A (es) Fusiones y conjugados de farmaco.
WO2013072813A3 (en) Cytotoxic peptides and antibody drug conjugates thereof
WO2013130683A3 (en) Xten conjugate compositions and methods of making same
EA201992456A2 (ru) Самостабилизирующиеся линкерные конъюгаты
UA110370C2 (en) Conjugates of amatoxin with improved linkages
WO2011123820A3 (en) Single isomeric conjugates of rhodamine dyes
WO2011086143A3 (en) Liver targeting domain antibodies
UA106900C2 (uk) Агоністичний dr5-зв'язувальний поліпептид
WO2012072731A3 (en) Improved anti-serum albumin binding single variable domains
WO2011112566A3 (en) Basigin binding proteins
MX2013002055A (es) Variantes anti-enlace de albumina de suero mejodas.
MX2015014198A (es) Anticuerpos cuyo objetivo es m-csf.
CA3036643C (en) Cmet monoclonal binding agents, drug conjugates thereof and uses thereof
WO2014044793A3 (en) Cd22-binding peptides
EP2569327A4 (en) EIF4E BINDING PEPTIDES
WO2008005470A3 (en) Polypeptides that bind membrane proteins
WO2016005474A8 (en) Site selective conjugation of an oligonucleotide conjugate or a small molecule to a metal binding protein
WO2012136792A3 (en) Cck compositions
CR20110473A (es) Variantes de union a anti-albúmina de suero mejoradas.